CURRENT REPORT 23/2024

June 14, 2024

Ryvu Therapeutics presents clinical and preclinical data on RVU120 at the 2024 European Hematology Association Congress

The Management Board of Ryvu Therapeutics S.A. with its registered office in Krakow, Poland ("**Company**", "Ryvu") announces that on June 14, 2024 the Company has presented clinical and preclinical data from RVU120 at the 2024 European Hematology Association Congress (EHA), June 13-16, Madrid, Spain.

Details on the poster presentations are as follows:

Poster Title: RVU120, a first-in-class CDK8 inhibitor for the treatment of relapsed/ refractory AML and high-risk MDS: preliminary results from two ongoing studies.
Poster Number: P600
Session date and time: Friday, June 14 (9:00 CET on the online platform, 18:00 CET for the poster presentation)

The poster includes data on 30 evaluable patients out of 38 total dosed patients in the phase I trial (RIVER-51) and initial data from the phase II trial (RIVER-52).

- RVU120 as single agent showed clinical benefit in a heavily pretreated population with AML and HR-MDS in the phase I trial CLI120-001 (RIVER-51). The strongest evidence of benefit was observed in patients with NPM1 and/or DNMT3A mutations, and in patients with HR-MDS.
- At the poster presentation's data cut-off, RIVER-52, the phase II trial of RVU120 in monotherapy for patients with relapsed/refractory AML and HR-MDS, had immature data for efficacy assessment in the target population, even though preliminary signs of clinical benefit had been observed in ongoing patients.
- The safety and tolerability of RVU120 at the RP2D of 250 mg administered every other day was confirmed in patients treated in both trials, with mild or moderate gastrointestinal events being the most frequently reported.

Poster Title: Synergistic potential of RVU120, a first-in-class CDK8/CDK19 inhibitor, with venetoclax in AML: preclinical and initial clinical insights.
Poster Number: P525
Session date and time: Friday, June 14 (9:00 CET on the online platform, 18:00 CET for the poster presentation)

- Ryvu presents a mechanism of synergy between RVU120 and venetoclax in preclinical models of acute myeloid leukemia (AML).
- The combination of RVU120 and venetoclax leads to caspase-dependent degradation of MCL-1 protein and represses inflammatory and AML oncogenic pathways at the transcriptomic level in AML cells.
- RVU120, when combined with venetoclax, exerts cytotoxic and differentiating effects on leukemic stem cells (LSCs) from a hierarchical AML model, surpassing the efficacy of venetoclax alone.
- By countering therapeutic failure caused by persistent LSCs and MCL-1-mediated venetoclax resistance, this combination offers hope to patients with AML in the refractory and the frontline setting.
- Initial data from the ongoing Phase II study RIVER-81 demonstrate the safety of RVU120 in combination with venetoclax at the initial dose level in patients with relapsed/refractory AML. Enrollment is currently ongoing in Cohort 2.

Poster Title: CDK8/19 Inhibition: A Promising Therapeutic Strategy in Myeloproliferative Neoplasms.
Poster Number: P1018
Session date and time: Friday, June 14 (9:00 CET on the online platform, 18:00 CET for the poster presentation)

- In murine models of disease, RVU120 effectively attenuates myeloproliferative neoplasms (MPN) phenotypes (single-agent or combined with ruxolitinib (RUX)) partly through downregulation of pro-inflammatory cytokines.
- RVU120 exhibits synergy with a whole class of JAK inhibitors and the BET inhibitor pelabresib. These exciting findings open new potential therapeutic options for MPN patients, including myelofibrosis.
- The combination of RVU120 and RUX acts synergistically by downregulating JAK/STAT signaling and inflammatory pathways at the transcriptomic level.
- Based on compelling preclinical results, Ryvu Therapeutics is launching the clinical study POTAMI-61 (NCT06397313). This study will evaluate RVU120 as a single agent or in combination with ruxolitinib in patients with myelofibrosis.

Investor Event:
Ryvu will host a webinar on Friday, June 14, at 9:30 CET, covering the latest data and potential of RVU120. To join the webcast, please register here:
https://ryvu.clickmeeting.com/ryvu-eha-2024-results

Disclaimer: This English language translation has been prepared solely for the convenience of English-speaking readers. Despite all the efforts devoted to this translation, certain discrepancies, omissions or approximations may exist. In case of any differences between the Polish and the English versions, the Polish version shall prevail. Ryvu Therapeutics S.A., its representatives and employees decline all responsibility in this regard.

Legal basis: Article 17.1 of MAR

Representatives of the Issuer:

- Paweł Przewięźlikowski – President of the Management Board
- Hendrik Nogai – Member of the Management Board